Day One Biopharmaceuticals Inc (DAWN) - Total Assets
Based on the latest financial reports, Day One Biopharmaceuticals Inc (DAWN) holds total assets worth $513.78 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Day One Biopharmaceuticals Inc - Total Assets Trend (2019–2024)
This chart illustrates how Day One Biopharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see DAWN company net worth for the company's overall valuation and market capitalisation.
Day One Biopharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Day One Biopharmaceuticals Inc's total assets of $513.78 Million consist of 96.5% current assets and 3.5% non-current assets. Review Day One Biopharmaceuticals Inc balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.4% |
| Accounts Receivable | $13.88 Million | 2.4% |
| Inventory | $3.32 Million | 0.6% |
| Property, Plant & Equipment | $4.71 Million | 0.8% |
| Intangible Assets | $15.63 Million | 2.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Day One Biopharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Day One Biopharmaceuticals Inc stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Day One Biopharmaceuticals Inc's current assets represent 96.5% of total assets in 2024, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 21.4% of total assets in 2024, down from 100.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 2.7% of total assets.
Day One Biopharmaceuticals Inc Competitors by Total Assets
Key competitors of Day One Biopharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Hugel Inc
KQ:145020
|
Korea | ₩1.13 Trillion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Beijing Scitop Bio Tech Co Ltd
SHE:300858
|
China | CN¥2.03 Billion |
Day One Biopharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.68 | 14.62 | 22.58 |
| Quick Ratio | 8.55 | 14.55 | 22.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $433.50 Million | $541.25 Million | $43.08 Million |
Day One Biopharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Day One Biopharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.51 |
| Latest Market Cap to Assets Ratio | 1.94 |
| Asset Growth Rate (YoY) | 55.0% |
| Total Assets | $582.79 Million |
| Market Capitalization | $1.13 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Day One Biopharmaceuticals Inc's assets above their book value (1.94x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Day One Biopharmaceuticals Inc's assets grew by 55.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Day One Biopharmaceuticals Inc (2019–2024)
The table below shows the annual total assets of Day One Biopharmaceuticals Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $582.79 Million | +54.98% |
| 2023-12-31 | $376.05 Million | +7.73% |
| 2022-12-31 | $349.06 Million | +20.44% |
| 2021-12-31 | $289.82 Million | +534.72% |
| 2020-12-31 | $45.66 Million | +67.02% |
| 2019-12-31 | $27.34 Million | -- |
About Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory… Read more